The impact of chronic exposure to Bevacizumab on EpCAM-based detection of circulating tumor cells was further explored [19], and a decrease in the expression of EpCAM 40 kDa isoform and of cytokeratins was proved, although no evidence for EMT in treated cells was observed. This evidence concerns the gene EPCAM and neoplasm.